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ABSTRACT
We have previously established a stroma-free culture
with Flt-3 ligand (FL), stem cell factor (SCF), and throm-
bopoietin (TPO) that allows the maintenance and the
expansion for several weeks of a cord blood (CB) CD34+
cell population capable of multilineage and long-lasting
hematopoietic repopulation in non-obese diabetic/ severe
combined immunodeficient (NOD/SCID) mice.
In this work the kinetics of megakarocyte (Mk)-
engraftment that is often poor and delayed in CB trans-
plantation, and human platelet (HuPlt) generation in
NOD/SCID mice of baseline CD34+ cells (b34+), and of
CD34+ cells reisolated after a 4-week expansion with
FL+SCF+TPO (4w34+) were compared.
With b34+ cells Mk-engraftment was first seen at
week 3 (CD41+: 0.4%); 4w34+ cells allowed a more rapid
Mk-engraftment (at weeks 2 and 3 the CD41+ cells were
0.3% and 0.8%). Circulating HuPlts were first seen at
weeks 2 and 1, respectively.
Mk-engraftment levels of b34+ and 4w34+ cells 6-8
weeks after transplantation were similar (12 ± 3.5 versus
15 ± 5% CD45+; 1.3 ± 0.5 versus 1.8 ± 0.5% CD41+ cells).
Also serial transplant experiments were performed with
expanded and reselected CB cells. In secondary and ter-
tiary recipients the Mk population was detected with bone
marrow fluorescence-activated cell sorter analysis; these
experiments indicate the effective long-term repopulation
of expanded cells. Selected CD34+ cells after a 4-week
expansion with FL+SCF+TPO are more efficient in Mk
engraftment than the same number of unmanipulated
cells. Stem Cells 2004;22:135-143
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INTRODUCTION
The numbers of hematopoietic progenitors and stem cells
in cord blood (CB) may be enough to support engraftment in
children, but their ex-vivo expansion might be required to
successfully engraft an adult. Moreover, a long-lasting severe
post-transplant thrombocytopenia is often observed even in
pediatric patients [1-8].
Therefore, two important aspects of the biology of ex-
vivo expanded cells relate to cultured cells: either maintaining
their self-renewal capacity and multilineage differentiation
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potential, or improving their short-term engraftment ability
when transplanted into myeloablated recipients. Several
growth factor combinations have been tested to identify
suitable culture conditions to induce expansion of primitive
stem cells (SCs). So far, only a few studies have shown that
primitive non-obese diabetic severe combined immuno-
deficient (NOD/SCID) mouse repopulating stem cells from
CB can be expanded (a few or several-fold) after in vitro
culture [9-13].
In CB transplants, the megakaryocyte (Mk) lineage
takes the longest time to engraft. However, to date, if only
a few experimental studies have addressed the issue of the
short-term engraftment ability of fresh CB SCs, even fewer
have addressed that of ex-vivo expanded SCs [14-16].
Using the NOD/SCID mouse model, the short-term as well
as the long-term repopulating ability and the differentiation
and maturation potential of human hematopoietic lineages
in an in vivo experimental model can be analyzed [17, 18].
Thus, by means of this in vivo model we set up experi-
ments to evaluate the Mk lineage reconstitution ability and
functional platelet release by baseline CB CD34+ cells (b34+)
and CB CD34+ cells reisolated after a 4-week expansion
(4w34+) in the presence of Flt-3 ligand (FL), thrombopoietin
(TPO), and stem cell factor (SCF).
MATERIALS AND METHODS
Recombinant Human Cytokines
The following recombinant purified human cytokines
were used in these studies: recombinant human (rh) TPO, 
a generous gift from Kirin Brewery (Tokyo, Japan;
http://www.kirin.co.jp/english/), rh interleukin-6 (IL-6)
(PeproTech Inc.; Rocky Hill, NJ; http://www.peprotech. com),
rhIL-3 (Sandoz; Basel, Switzerland; http://www.sandoz.com),
rhFL kindly provided by S.D. Lyman (Immunex Corp; Seattle,
WA; http://www.immunex.com), and rhSCF (a gift from
Amgen; Thousand Oaks, CA; http://www.amgen. com).
Human Cells
Umbilical CB was obtained following informed written
consent at the end of full-term deliveries, by clamping and cut-
ting the cord and draining blood into sterile collection tubes
containing the anticoagulant citrate-phosphate dextrose.
CD34+ Cell Purification and Culture
Mononuclear cells were isolated from CB using Ficoll
Hypaque (density 1.077 g/cm3; [Nyegaard; Oslo, Norway;
http://www.amershamhealth.com]) density centrifugation.
The CD34+ fraction was isolated with superparamagnetic
microbead selection using high-gradient magnetic field and
MiniMACS column (Miltenyi Biotech; Gladbach, Germany;
http://www.miltenyibiotech.com). The efficiency of the purifi-
cation was verified by flow cytometry counter staining with a
CD34-phycoerythrin (PE) HPCA-2 antibody (Becton
Dickinson; San Jose, CA; http://www.bd.com). In the cell frac-
tion containing purified cells, the percentage of CD34+ cells
ranged from 90%-98%. These cells were denominated b34+.
Long-Term Expansion Cultures for Primitive Repopulating
Cells
Stroma-free expansion cultures were performed as previ-
ously described [11, 19, 20]. Briefly, CB CD34+ cells at 5 ×
104/ml in Iscove’s modified Dulbecco’s medium (GIBCO)
with 10% fetal calf serum (HyClone; Logan, UT;
http://www.hyclone.com) were inoculated into tissue culture
T75 flasks with FL (50 ng/ml), SCF (50 ng/ml), and TPO (10
ng/ml). Growth factors were added at the start of cultures and
then twice a week. Each week the cells were counted and the
same volume of fresh medium plus growth factors was added.
After 4 weeks all cells were harvested, washed, counted, and
then subjected to immunoselection with MiniMACS columns
as described above, to obtain CD34+ populations (denomi-
nated 4w34+) to be injected into sublethally irradiated
NOD/SCID mice. 4w34+ cells were 96%-98.7% pure; only
1.5%-2.8% of these cells were CD34+/CD41+.
Injection of Cells in NOD/SCID Mice
NOD/LtSz scid/scid NOD/SCID mice were purchased
from The Jackson Laboratory (Bar Harbor, ME; http://www.
jax.org) and maintained in the Centro di Immunologia ed
Oncologia Sperimentale animal facilities (Torino, Italy). All
animals were handled under sterile conditions and maintained
in cage microisolators. Sublethally irradiated (350 cGy of
total body irradiation from a 137Cs source) 6- to 8-week-old
mice were injected in the tail vein with 2.5 × 105 b34+ or 2.5
× 105 4w34+ cells. The mice were sacrificed 1, 2, 3, and 4
weeks (short-term reconstitution) post-transplant or after a
longer period of time (6 to 8 weeks post injection), and bone
marrow (BM) cells were flushed from femurs and tibias using
a syringe and 26-gauge needle to assess the number and types
of human cells.
The appearance of human platelets (HuPlts) in murine
peripheral blood (PB) 7, 14, 21, and 28 days after injection
was also assessed as described [21]. No growth factors
were administered to the animals.
Serial transplant experiments were performed as previ-
ously described [22]. Briefly, 20 to 40 × 106 unseparated BM
cells from a primary or a secondary mouse were injected i.v.
into a single sublethally irradiated secondary or tertiary
NOD/SCID mouse. Secondary and tertiary mice were sacri-
ficed 6 weeks post injection, and BM cells were harvested and
processed as described.
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Analysis of Murine BM
Flow cytometry was used to analyze the levels of
human cells in the BM of the mice; the cells were resus-
pended at 1 to 2 × 106 cells/ml and incubated with mouse
immunoglobulin G (Fluka Chemika Biochemika; Buchs,
Switzerland; http://www.wiz.uni-kassel.de) to block non-
specific binding to the Fc receptor. Cells were then incu-
bated with fluorescein isothiocyanate (FITC) or PE-labeled
monoclonal antibody (mAb) specific for human CD for 30
minutes at 4°C to quantify human hematopoietic cells.
Some cells from each suspension were similarly incubated
with isotype control mAbs labeled with FITC and PE
(CALTAG Laboratory; Burlingame, CA; http://www.cal
tag.com). After staining the cells were washed once in
phosphate-buffered saline with 0.1% bovine serum albumin
and 0.01% sodium azide. Contaminating RBCs were lysed
with EDTA 10–4 mol/l, KHCO3 10–3 mol/l, and NH4CL 0.17
mol/l. Flow cytometric analysis was performed using a
FACSVantage cytometer (Becton Dickinson). At least
20,000 events were acquired for each analysis. Analysis
was performed with CellQuest software (Becton
Dickinson).
The antibodies used were FITC-labeled antihuman CD41,
CD42 (DAKO; Glostrup, Denmark; http://www.dakocy
tomation.com), and PE-labeled antihuman CD14 (DAKO),
CD19 (CALTAG Laboratory), CD34 (Becton Dickinson),
CD71 (DAKO), and anti-GpA (DAKO). CD45 TRI-COLOR
conjugated (CALTAG Laboratory) was also used.
For human colony assays, 1 to 5 × 105 BM cells, accord-
ing to the levels of human engraftment, were plated in
plasma clot assays as previously reported [11] by substitut-
ing bovine plasma with pooled human AB plasma. Human
GM and erythroid colonies were enumerated after 14 days
of incubation at 37°C in a fully humidified atmosphere at
5% CO2 from triplicate dishes containing erythropoietin 
(3 U/ml), SCF (50 ng/ml), GM-CSF (20 ng/ml), and IL-3 
(5 ng/ml). Colony-forming units (CFU-Mk) were enumer-
ated after 12 days of cultures from triplicate dishes at the
immunofluorescence microscope after staining with an
FITC-conjugated mAb recognizing human GP IIb/IIIa
(CD41) [23, 24]. In the described culture conditions only
human colonies could be detected. At the various time
points BM cells from irradiated and not transplanted
NOD/SCID mice were cultured, but in no case could
human colonies be detected.
Human Platelet Detection in NOD/SCID Mouse Peripheral
Blood
Platelet appearance in murine PB 7, 14, 21, and 28 days
after injection was also assessed as described [21]. Briefly,
murine PB (10 µl) was incubated at room temperature with
FITC-conjugated anti-mouse CD41 (Becton Dickinson)
and PE-conjugated anti-human CD41 (DAKO) or isotype
control for 5 minutes and analyzed immediately by flow
cytometry. Fifty-thousand events were acquired with a pri-
mary gate set on a dual parameter histogram of log forward
light scatter and log side light scatter. Background fluores-
cence was assessed with platelets labeled with the FITC-
and PE-conjugated isotype control antibody. PB from
untransplanted mice and from a human donor was analyzed
as additional controls. A FACSVantage flow cytometry
(Becton Dickinson) was used for acquisition of platelet
data, and analysis was performed using CellQuest software
(Becton Dickinson).
Activation of Human Platelets by Thrombin
Aliquots of mouse PB (10 µl) were incubated with
thrombin (at a final concentration of 50 U/ml) for 10 min-
utes. After this incubation the platelet CD62P (CALTAG
Laboratory) expression was assessed by flow cytometry.
Live acquisition of 1,000 to 2,000 HuPlts events was per-
formed by gating human CD41PE+ events in the platelet
size range.
Statistical Analysis
Results of experimental points obtained from multiple
experiments are reported as the mean ± standard deviation
(SD). The significance of differences in mean value was
determined by using the Student’s t-test.
RESULTS
Megakaryocyte Reconstitution in NOD/SCID Mice by Baseline
and Expanded CD34+ Cells (b34+ and 4w34+)
To evaluate short-term Mk-engraftment, 2.5 × 105 b34+
cells were injected into cohorts of sublethally irradiated
NOD/SCID mice that were sacrificed 1, 2, and 3 weeks
after inoculation. BM cells of the sacrificed animals were
obtained from both femurs and tibias and assessed for the
presence of human hematopoietic cells. Human cells in the
murine BM were quantified for myeloid, lymphoid, ery-
throid, and Mk lineage antigen expression. Fluorescence-
activated cell sorter (FACS) analysis of the BM of the
sacrificed animals showed that at week 1 post-transplant
levels of human CD45+ cells were low but clearly
detectable (3.7 ± 2.8). Within the human cells, the most rep-
resented were the CD34+ and the CD19+ subpopulations
(Table 1). Erythroid cells, identified by CD71 and GpA
expression were also present. Surprisingly, no cells belong-
ing to the Mk lineage could be found. At week 2 post injec-
tion, the levels of human CD45+ cells were quite similar. At
week 3, human cell engraftment further increased. Only at
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this time point the Mk subpopulation, although at very low
percentages, became detectable (Table 1).
To evaluate the short-term Mk-engraftment capacity of
more expanded primitive cells, in five different experi-
ments, 2.5 × 105 CD34+ cells were cultured in triplicate
stroma-free liquid cultures in the presence of FL, SCF, and
TPO as described [11]. After 4 weeks of expansion they
yielded a mean of 48.5 ± 2.4 × 106 total cells that included
1.9 ± 0.43 × 106 CD34+ cells. Following immunoselection,
only 2.5 × 105 CD34+ (4w34+) cells were injected in each
mouse. In these mice the levels of human engraftment at
week 1 were similar to those found in b34+-transplanted mice
and increased with time. Here the growth of some CFU-Mk
colonies could be achieved. CFU-Mk number increased at
weeks 2 and 3 (Table 1). By contrast, in mice injected with
b34+ cells, no CFU-Mk colonies could be found at week 1.
Only at week 3 were there as many Mk colonies as those
found much earlier (week 1) in 4w34+ transplanted mice.
Long-term Mk-engraftment was evaluated in NOD/SCID
mice sacrificed 6-8 weeks after inoculation. Table 2 shows the
mean engraftment level of ten mice injected with 2.5 × 105
b34+ cells. Flow cytometry analysis showed that the human
cells belonged to all hematopoietic lineages; cells of the Mk
lineage were found in all mice. CFU-Mk colonies were
detected in plasma clot cultures seeded with the BM cells of
the transplanted animals (Table 2).
The results of injection of 2.5 × 105 4w34+ cells are
reported in Table 2. All the mice, after 6-8 weeks from the
injection, were successfully engrafted (10/10). The mean
engraftment level of the ten mice injected with this cell dose
was 15 ± 5%. FACS analysis showed that human cells
belonged to all hematopoietic lineages (not shown).
Moreover, five mice were transplanted with all of the
CD34+ cells generated by initial 2.5 × 105 CD34+ cells during
a 4-week expansion. At 6-8 weeks post-transplant the BM
engraftment levels were very high (79 ± 11.4) and the Mk
population was well-represented (3.6 ± 0.4% of the total BM).
The presence of human CFU-Mk in the BM of mice was
evaluated. Overall, 1,900 ± 302, 2,200 ± 159 and 8,259 ± 1,102
human Mk colonies were detected in mice transplanted with
b34+ and the two concentrations of 4w34+ cells, respectively.
To evaluate the effective long-term Mk-engraftment of
expanded cells, the unseparated BM cells of three primary
mice, harvested 6 weeks after injection of 2.5 × 105 4w34+
cells, were transplanted in three secondary and subsequently in
three tertiary sublethally irradiated recipients. In these experi-
ments of serial transplants, mice were successfully engrafted,
and the Mk population was well-represented [22] (Fig. 1).
Platelet Production in NOD/SCID Mice
The appearance of HuPlts in the mouse PB after CB injec-
tion was monitored from week 1 by FACS analyses. After total
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Table 1. Short-term engraftment of NOD/SCID mice transplanted with fresh (b34+) or ex vivo expanded (4w34+) cells
b34+ cells 4w34+ cells
Engraftment (%) 7 days 14 days 21 days 7 days 14 days 21 days
CD45+ 3.7 ± 2.8 4 ± 2.1 7.3 ± 1.5 2.7 ± 1.9 5.6 ± 3.3 6.9 ± 2.5
CD34+ 1.1 ± 0.5 1.2 ± 0.5 0.9 ± 0.4 1.2 ± 0.7 1.1 ± 0.5 0.9 ± 0.2
CD19+ 1.2 ± 0.7 1.6 ± 0.8 3.5 ± 1.4 0.9 ± 0.4 2.4 ± 1.1 3 ± 1.2
CD13+ 0.8 ± 0.4 0.9 ± 0.5 1.2 ± 0.3 0.4 ± 0.1 0.9 ± 0.3 1.2 ± 0.8
CD41+ 0* 0* 0.4 ± 0.2 0* 0.3 ± 0.1 0.8 ± 0.3
CD71+ GpA+ 0.3 ± 0.1 0.3 ± 0.1 0.8 ± 0.4 0.2 ± 0.1 0.4 ± 0.2 1.3 ± 0.3
Total colonies/mouse§ 1,945 ± 32 2,102 ± 32 2,307 ± 65 2,456 ± 43 4,986 ± 56** 5,011 ± 43**
Mk-colonies/mouse† 0 42 ± 23 73 ± 28 72 ± 15** 210 ± 32** 259 ± 34**
Mice were injected with 2.5 × 105 (b34+) cells and with the same number of CD34+ cells immunoselected from week 4 expansion cultures (4w34+).
Results show the mean ± SD of human cell subpopulations detected by FACS analysis performed in the murine BM 1, 2, and 3 weeks after transplant
(4 mice per experimental point, 3 separate experiments).
*Below FACS detection limit (< 0.1% of human cells).
§Mean ± SD of the number of human CFU-GM + BFU-E + CFU-GEMM + CFU-Mk calculated/mouse. The number was obtained by plating 1 to 5
× 105 total BM cells of the engrafted mice (three dishes per point), taking into account that BM cells of femurs and tibias represent 25% of the entire
BM [31]. Colony number was calculated by multiplying the mean number of colonies generated by 5 × 105 unseparated mouse BM cells × the 
number of cells harvested from the femurs and the tibias of each mouse × 4 and by dividing the total number by 5 × 105.
†CFU-Mk were separately scored on day 12 at the immunofluorescence microscope, after staining of three additional dishes with FITC-conjugated
anti-human GP IIb/IIIa monoclonal antibody.
**p < 0.05 as compared to the values obtained injecting b34+.
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Table 2. Six- to 8-week engraftment of NOD/SCID mice transplanted with b34+ and 4w34+ CB cells
Engraftment (%) b34+ cells (2.5 × 105) 4w34+ cells (2.5 × 105) tot 4w34+ cells (2.15 ± 1.7 × 106)
CD45+ 11.9 ± 3.5* 15 ± 5 79 ± 11.4
CD34+ 1.3 ± 0.5 1.5 ± 0.9 7.1 ± 3.6
CD19+ 6.1 ± 3.1 7.6 ± 2.3 50 ± 9.8
CD13+ 1.9 ± 0.7 2.3 ± 1.3 15 ± 4.5
CD41+ 1.3 ± 0.5 1.6 ± 0.5 3.6 ± 0.4
CD71+ GpA+ 0.8 ± 0.4 1 ± 0.5 2.5 ± 1.1
Human colonies/mouse 31,700 ± 2,200 52,200 ± 1,600** 125,600 ± 13,600†
Human CFU-Mk/mouse 1,900 ± 300 2,200 ± 150** 8,250 ± 1,100†
*Ten mice were injected with 2.5 × 105 b34+ cells, 10 mice with 4w34+ 2.5 × 105 cells, and five mice with all of the CD34+ cells generated by initial
2.5 × 105 CD34+ cells after 4 weeks of ex vivo expansion with FL, SCF, and TPO (1.93 to 2.35 × 106 4w34+).
Results are expressed as the mean  ± SD of % of human cells observed with FACS analyses performed on murine BM 6 to 8 weeks after transplant.
Colony counts were performed as described in Table 1, with the exception that for each dish, 1 × 105 unseparated mouse BM cells were plated.
Results are from five separate expansion experiments (two mice per experiment).
**not significant
†p < 0.05 compared to values obtained by inoculating b34+ cells
Figure 1. Human megakaryocyte engraftment in serial transplant NOD/SCID mice. FACS profile of marrow cells from a representative
NOD/SCID mouse that 6 weeks earlier was transplanted with 2.5 × 105 4wCD34+ (CD34+cells immunoselected after 4 weeks of expansion in
presence of FL, SCF, and TPO). The BM of this primary mouse was injected into a secondary sublethally irradiated NOD/SCID mouse sacri-
ficed 6 weeks after transplantation; the BM of this mouse was injected in a tertiary mouse also sacrificed 6 weeks after transplantation. Human
CD45+ cells represented 22% of the BM cells of the primary mouse, 7% of the secondary recipient that had received 25 × 106 unseparated BM
cells of the primary mouse, and 2.5% of the tertiary mouse that received 30 × 106 total BM cells of the secondary recipient. FACS analyses of
human CD41 expression in the BM of primary, secondary, and tertiary mice were performed on total BM: the percentages of CD41+ cells were
respectively: 1.3%, 0.6%, and 0.1%. The bottom panels represent the analysis of the CD41+ population within the CD45+ cell gate in each of
the three recipients.
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body irradiation murine platelets decreased from a mean of
1.45 ± 0.3 × 1012/l to a mean of 0.45 ± 0.1 × 1012/l at week 1
and increased to a mean of 0.8 ± 0.2 × 1012/l at week 3.
HuPlts were detected by staining PB cells with an anti-
CD41 mAb against HuPlts surface GP IIb/IIIa. After trans-
plantation of b34+ cells, a maximum of 0.3% HuPlts was
detected only at week 3 (Fig. 2). At week 4 HuPlt count was
a mean of 4.5%; the percentage of the HuPlts was similar at
6-8 weeks after transplant in some transplanted mice. By
contrast in the PB of mice injected with 2.5 × 105 4w34+ cells,
0.5% of HuPlts were seen as early as week 1, even if the
human CD41+ cells in the murine BM were below the FACS
detection limit (<0.1%). Plts were a mean of 0.7% at week 2
and 12% at week 3 (Fig. 2 and Fig. 3A). The HuPlts persisted
in murine PB even 6-8 weeks after transplant. When the mice
were transplanted with all of the 4w34+ cells generated by
initial 2.5 × 105 CD34+ cells, platelet levels at week 1 were
very high (6.8%) (Fig. 2).
HuPlt activation in response to in vitro challenge with
thrombin was tested. Thrombin induces granule secretion
resulting in CD62P expression on the platelet membrane.
After thrombin stimulation, the expression of CD62P on
human CD41+ platelets was increased (Fig. 3B).
DISCUSSION
The xenogenic NOD/SCID mouse model offers one of
the best approaches for investigating the in vivo repopulating
ability of human hematopoietic tissues [14-16, 25-28]. In such
a model we previously demonstrated that CB CD34+ cells
could be expanded for several weeks in stroma-free cultures
containing FL, TPO, and SCF and that expanded cells main-
tained and increased their in vivo repopulating capacity [11,
12, 22]. Moreover, we have previously demonstrated that
basal and expanded CD34+ cells, subsequently “committed”
in vitro toward the Mk lineage, gave a rapid and transient
Mk engraftment [29].
In this work CB CD34+ cells, isolated after 4 weeks of
expansion (4w34+ cells), were injected in NOD/SCID mouse
recipients. These experiments show that purified 4w34+ cells
retain their capacity to provide long-term support of the
megakaryocytopoiesis in the BM of several generations of
sublethally irradiated NOD/SCID mice. The levels of human
hematopoietic reconstitution were similar in mice trans-
planted with same numbers of b34+ and 4w34+ CB cells (or
slightly higher with the expanded cells). As already reported,
all hematopoietic lineages including the Mk, were found in
the NOD/SCID mice BM at least 6 to 8 weeks post-trans-
plant of expanded cells [11]. The Mk lineage was represented
by CD41+ cells and by more immature CFU-Mk.
Although previous studies reported that human CB, BM,
and PB could generate human CD41+ cells in NOD/SCID
mice [16, 29], only a few papers have provided evidence for
human Mk development and terminal differentiation into
functional HuPlts with human CD34+ PB and CB cells [14,
15]. To our knowledge this research is the first that shows
expanded CB cells are better than unmanipulated cells in
terms of Mk short-term engraftment and terminal Mk matu-
ration (platelets production was already found 1 week after
the injection of ex vivo expanded CD34+ cells).
In fact, these studies indicate that short-term engraftment
is achieved with both baseline and expanded CD34+ cells.
Furthermore, while Mk reconstitution is slower with b34+
cells (a few Mk cells and CFU-Mk appear in the BM, and
platelets are found in the PB only at week 3 and 2 post-trans-
plant, respectively), Mk-engraftment by purified 4w34+ cells
is detectable earlier. The speed and degree of Mk-engraft-
ment by expanded cells are higher in the latter case. Terminal
differentiation of Mk progenitors and precursors is also
achieved in this case, as HuPlts are well detected in the PB
from week 1 on. Probably at 1 week post-injection in the BM
of 4w34+ transplanted mice and at week 2 post-injection in
the BM of b34+ transplanted mice, there were a few human
CD41+ cells that were able to produce platelets, but the level
in total BM (murine and human cells) is below the FACS
detection limits.
Our findings on b34+ cells are consistent with those
reported by Verstegen et al. who found peak, but low lev-
els, of HuPlts at week 2 (0.1% to 0.2%) in macrophage-
depleted SCID mice injected with CB CD34+ cells [15]. 
A previous study by Güenechea et al. reported that day 
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Figure 2. Human platelet appearance. Kinetics of HuPlt appearance in the PB
of NOD/SCID mice injected with 2.5 × 105 baseline CD34+ cells, 2.5 × 105 CD34+
cells immunoselected from 4-week expanded cultures and with all the CD34+
progeny of 2.5 × 105 initial CD34+ cells expanded for 4 weeks. Results show the
mean ± SD of the percentage of HuPlts detected by FACS analysis in the murine
PB at the indicated time points after transplantation (4 mice per experimental
point, 3 separate experiments).
Bruno, Gunetti, Gammaitoni et al. 141
104103102101100
10
4
10
3
10
2
10
1
10
0
SS
C 
He
ig
ht
FSC Height
104103102101100
10
4
10
3
10
2
10
1
10
0
SS
C 
He
ig
ht
FSC Height
104103102101100
10
4
10
3
10
2
10
1
10
0
SS
C 
He
ig
ht
FSC Height
12%
104103102101100
10
4
10
3
10
2
10
1
10
0
CD
11
 
hu
m
an
 P
E
SSC Height
104103102101100
10
4
10
3
10
2
10
1
10
0
PE
SSC Height
104103102101100
10
4
10
3
10
2
10
1
10
0
PE
SSC Height
104103102101100
10
4
10
3
10
2
10
1
10
0
PE
SSC Height
104103102101100
10
4
10
3
10
2
10
1
10
0
PE
SSC Height
104103102101100
10
4
10
3
10
2
10
1
10
0
PE
SSC Height
IsotypeIsotypeIsotype
104103102101100
10
4
10
3
10
2
10
1
10
0
CD
41
 P
E 
hu
m
an
CD 62P human
104103102101100
10
4
10
3
10
2
10
1
10
0
CD
41
 P
E
CD 62P human
Pre-thrombin Post-thrombin
Transplanted mouse
peripheral blood
Human
peripheral blood
(positive control)
Untransplanted mouse
peripheral blood
(negative control)
A
B
Figure 3. Flow cytometric analysis of
human platelets in peripheral blood of
NOD/SCID mice. A) PB samples (from a
representative untransplanted mouse, a
normal human donor, and a mouse
injected 3 weeks previously with 2.5 ×
105 4w34+ cells) were labeled with a mAb
against human CD41a. Analysis was
performed within the platelet population
gate based upon forward and side scat-
ter. B) Flow cytometric analysis of
HuPlts from a mouse transplanted 3
weeks previously with 2.5 × 105 4w34+
cells before and after thrombin stimula-
tion. On the y-axis PE-anti-human CD41a, on the x-axis FITC-anti-human CD62P. CD62P is expressed only on activated platelets. FACS
analysis is carried out within the gate of HuPlts.
7-expanded CB cells engraft in the NOD/SCID mouse more
slowly than the unmanipulated counterpart [30]. Our data
indicate that even equal numbers of expanded and reiso-
lated CD34+ cells, compared to baseline CB cells, provide
similar engraftment at 1, 2, and 3 weeks post-transplant in
terms of total CD45+ cells and a faster Mk reconstitution. If
baseline cells and the entire expansion equivalents obtained
in the present setting are compared, then marrow engraft-
ment at both early time points (25% CD45+ at week 1) and
at the standard 6-8 weeks is much higher with 4w34+-
expanded cells. Culture conditions, in particular growth
factor combinations employed in the two studies, are quite
different, and this explains the opposite findings. This sug-
gests that several aspects of cell expansion and manipula-
tion must be carefully studied, especially the growth factor
combinations to be adopted, before a clinical protocol is
implemented.
In conclusion, by means of serial transplants we show that
ex-vivo expanded cells are capable of sustained long-term Mk-
engraftment. Short-term engraftment by ex vivo expanded
cells seems even more efficient than with unmanipulated cells.
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